City of Hope

Xiuli Wang

Stephen J Forman

Christine E Brown

Don Jeffrey Diamond

John C Williams

Lawrence Stern

Joseph Cohen

Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in vivo expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.

Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy

Methods for treating AL amyloidosis using chimeric antigen receptors targeting CS1 are described.

CS1 targeted chimeric antigen receptor-modified T cells for treatment of AL amyloidosis

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

CS1 targeted chimeric antigen receptor-modified T cells

Nucleic acid molecules that include a nucleotide sequence encoding a chimeric antigen receptor (CAR) and a nucleotide sequence encoding a protease sensitive scFv, wherein the chimeric antigen receptor comprises: an scFv targeting a tumor antigen, a spacer, a transmembrane domain, a co-stimulatory domain, and a CD3&#x3b6; signaling domain; and the protease-sensitive scFv and the scFv target the same tumor antigen are described.

Growing community of inventors

Duarte, CA, United States of America

Xiuli Wang